Last reviewed · How we verify
Durvalumab (MEDI4736)
Durvalumab is a monoclonal antibody that blocks PD-L1, preventing tumor cells from evading immune attack and allowing T cells to recognize and kill cancer cells.
Durvalumab is a monoclonal antibody that blocks PD-L1, preventing tumor cells from evading immune attack and allowing T cells to recognize and kill cancer cells. Used for Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy, Metastatic or locally advanced urothelial carcinoma, Biliary tract cancer.
At a glance
| Generic name | Durvalumab (MEDI4736) |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Durvalumab binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the interaction with PD-1 on T cells. This prevents the immunosuppressive signal that tumors use to escape immune surveillance. By restoring T-cell function, durvalumab enables the body's immune system to mount an effective anti-tumor response.
Approved indications
- Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy
- Metastatic or locally advanced urothelial carcinoma
- Biliary tract cancer
- Gastric or gastroesophageal junction adenocarcinoma
Common side effects
- Fatigue
- Pneumonitis
- Diarrhea
- Nausea
- Decreased appetite
- Immune-mediated hepatitis
- Immune-mediated colitis
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Durvalumab (MEDI4736) CI brief — competitive landscape report
- Durvalumab (MEDI4736) updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI